El trading conlleva riesgos
Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento.
El trading conlleva riesgos
Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento.
Español (Latinoamérica)
Amgen Inc
Cerrado
SectorSalud
369.16 0.47
Resumen
Variación precio
24h
Mínimo
360.49
Máximo
369.59
Ingresos | -1.9B 1.3B |
|---|---|
Ventas | 339M 9.9B |
P/B Media del Sector | 27.105 66.845 |
BPA | 5.29 |
Rentabilidad por dividendo | 2.45 |
Margen de beneficio | 13.47 |
Empleados | 31,500 |
EBITDA | -839M 5.1B |
Recomendaciones | Comprar |
|---|---|
Estimación a 12 meses | +0.78% upside |
Rentabilidad por dividendo Media del Sector | 2.45% 2.25% |
|---|---|
Próximas Ganancias | 30 abr 2026 |
Próxima Fecha de Ex Dividendo | 15 may 2026 |
Capitalización de Mercado | 22B 208B |
|---|---|
Apertura anterior | 368.69 |
Cierre anterior | 369.16 |
Noticias sobre sentimiento de mercado
By Acuity
35%
65%
103 / 351 Clasificación en Healthcare
Puntuación técnica
By Trading Central
Confianza
Very Strong Bearish Evidence
Amgen Inc Gráfico
El rendimiento pasado no es un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
Amgen Inc Esperado
Precio Objetivo
By TipRanks
0.78% repunte
Estimación a 12 meses
Media 370.45 USD 0.78%
Máximo 432 USD
Mínimo 295 USD
De acuerdo con 24 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Amgen Inc Dist en los últimos 3 meses.
Sentimiento
By Acuity
103 / 351 Clasificación en Salud
Noticias sobre sentimiento de mercado
Coyuntura alcista
Volatilidad
Por debajo de la media
Volumen de Noticias (RCV)
Por debajo de la media
Finanzas
Gastos de venta y administración
Gastos operativos
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
Gasto por intereses de deuda
EBITDA
Beneficio operativo
$
Acerca de Amgen Inc
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Live chat